[ad_1]
Rise and shine, another busy day is on the way. We can tell because the official mascots got an early start chasing down various varmints darting about the Pharmalot campus. And then there is the noisy parade of vehicles passing nearby on their way to who knows what? As for us, we are firing up the trusty coffee kettle to brew another cup of stimulation. Our choice today is roasted coconut. Please feel free to join us. Meanwhile, the time has come to get cracking. So here is the latest laundry list of interesting items for you to peruse. We hope you have a smashing day and, of course, do keep in touch. Best of luck, everyone. …
Global drugmakers face a battle in 2026 to secure higher prices for their prescription medicines in Europe after agreeing to cut U.S. pricing last year under pressure from President Trump, Reuters explains. Tougher negotiations could lead drugmakers to delay launches of new medicines in parts of Europe, potentially limiting patient access to them, according to several industry investors, a lobbyist and a pharmaceutical executive. European countries pay around one-third less than the U.S. because they have national health systems that negotiate the prices with drugmakers and may delay purchasing them to get a better price. Many drugmakers warned last year that Europe risks losing access to new medicines unless governments change how health systems assess and pay for them.
It’s not just weight that returns after going off GLP-1s, but also concerning markers of heart disease risk, STAT says, citing a systematic review published Wednesday in the BMJ. Those reversals are worse than what happens when people stop weight loss programs that aren’t based on drugs, known as behavioral weight management. University of Oxford researchers reviewed 37 studies with more than 9,000 participants to find that stopping obesity drugs reversed the drugs’ beneficial effects on blood sugar, high cholesterol, and high blood pressure. Regardless of how much weight was shed, those diminishing upsides were faster and more pronounced in people who stopped taking the weight-management medications compared to people who stopped participating in regimens such as the Diabetes Prevention Program.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
[ad_2]
Source link
